AstraZeneca Results Presentation Deck

8 Q1 2021: total revenue +11% Vaccine contributed 4% of growth Total revenue growth, per cent FY 2015 T FY 2016 FY 2017 Total revenue excluding vaccine increased by 7% Q1 2018 Q2 2018 Q3 2018 14% 11% 18% Q4 2018 Q1 2019 Q2 2019 22% Q3 2019 5% 17% Q4 2019 Q1 2020 11% Q2 2020 Total revenue excluding vaccine (with negative growth in dark grey) Pandemic COVID-19 vaccine Changes at CER. 3% Q3 2020 10% Q4 2020 4% 7% Q1 2021 Brilinta Bevespi Koselugo Breztri New medicines the major contributor +$0.8bn incremental revenue of the new medicines compared to Q1 2020¹ Lokelma Enhertu Fasenra roxadustat Imfinzi Tagrisso Calquence Lynparza Farxiga Oncology New CVRM Respiratory & Immunology Absolute values at CER. 1. Total revenue for Farxiga, Lynparza, Tagrisso, Calquence, Imfinzi, Fasenra, roxadustat, Enhertu, Lokelma, Breztri, Koselugo, Bevespi and Brilinta. $m 200 150 100 50 0 -50 3

View entire presentation